Former Chief Scientific Officer · Amneal Pharmaceuticals, Inc. (AMRX)

Pradeep Bhadauria

FY2019 is the first fiscal year CompBrief holds for Pradeep Bhadauria as a named executive officer of Amneal Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$3,356,829

Salary $399,808Stock awards $999,997Bonus $750,000

4th of 10 named executive officers at Amneal Pharmaceuticals by FY2019 total.

10 named officers on file for Amneal Pharmaceuticals, FY2019

Pradeep Bhadauria’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 3 equity grants, each cited to its filing
  • AMRX’s disclosed peer group of 14 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Amneal Pharmaceuticals’s whole pay program stands against its peers

  • Amneal Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AMRX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed March 23, 2020 (DEF 14A).

Free

Get Pradeep Bhadauria’s full pay file as a PDF — free

More than this page: up to 10 years of Pradeep’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Pradeep Bhadauria compensation by year

Amneal Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as Amneal Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019
Salary$399,808
Bonus$750,000
Stock awards$999,997
Option awards$1,150,768
Non-equity incentive$0
Pension and deferred compensation$0
All other$56,256
Total$3,356,829

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Amneal Pharmaceuticals, Inc. DEF 14A filed March 23, 2020, accession 0001308179-20-000070, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Amneal Pharmaceuticals, Inc. filed document, accession 0001308179-20-000070. Every figure is read from that document and cited to the page and table it appears in. Filed March 23, 2020.

Equity holdings

unvested awards at FY2019 year-end
TypeUnvested unitsValue at year-endExercise price
RSU75,301$362,951—
Option153,486—$2.75

Per the Outstanding Equity Awards at Fiscal Year-End table in Amneal Pharmaceuticals, Inc.'s FY2019 proxy; value at the fiscal year-end close, as the company printed it.

Amneal Pharmaceuticals’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Robert StewartFormer President & CEO$9,525,800
Paul BisaroFormer Executive Chairman$4,119,314
David BuchenFormer SVP, Chief Legal Officer$3,651,747
Pradeep Bhadauria · this pageFormer Chief Scientific Officer$3,356,829
Andrew BoyerEVP, Commercial Operations$3,113,079
Todd BranningFormer SVP & CFO$2,655,963
Nikita ShahEVP, CHRO & Strategic Planning Officer$2,541,929
Bryan ReasonsFormer SVP & CFO$1,851,479
Chintu PatelCo-Chief Executive Officer$339,600
Chirag PatelPresident & Co-Chief Executive Officer$337,967

The full Amneal Pharmaceuticals compensation record

free company brief

This page is one person within Amneal Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Amneal Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Amneal Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Pradeep Bhadauria's compensation dossier · One-time report. No refunds.